Trastuzumab: beside a new treatment under test

261 studies: a new drug, cell therapy or vaccine is what the study tests. Page 3 of 3. Open to participants first (55), then studies with results posted, then the rest; newest registration first within each.

• A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric CancerCompletedNCT01746771Phase 1/2Report a problem
• Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTerminatedNCT01705340Phase 1Report a problem
• GRN1005 for Brain Metastases From Breast or Lung CancerWithdrawnNCT01679743Phase 2Report a problem
• Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric CancerCompletedNCT01602406Phase 1Report a problem
• Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing ChemotherapyCompletedNCT01594177Phase 2Report a problem
• Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)TerminatedNCT01512199Phase 1/2Report a problem
• GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain MetastasesCompletedNCT01480583Phase 2Report a problem
• Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on TrastuzumabWithdrawnNCT01479179Phase 1/2Report a problem
• A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to TrastuzumabCompletedNCT01471847Phase 1Report a problem
• Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab OnlyCompletedNCT01434303Phase 1Report a problem
• Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast CancerCompletedNCT01423123Phase 1Report a problem
• Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive PatientsTerminatedNCT01402401Phase 2Report a problem
• An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.CompletedNCT01386580Phase 1/2Report a problem
• Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast CancerStatus unknownNCT01304797Phase 1Report a problem
• A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive CancerCompletedNCT01304784Phase 1Report a problem
• Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast CancerCompletedNCT01300962Phase 1Report a problem
• A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without TrastuzumabCompletedNCT01285466Phase 1Report a problem
• Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With TrastuzumabCompletedNCT01271920Phase 1/2Report a problem
• A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast CancerCompletedNCT01265927Phase 1Report a problem
• Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast CancerTerminatedNCT01254136Phase 1/2Report a problem
• Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based RegimenCompletedNCT01042925Phase 1/2Report a problem
• A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast CancerCompletedNCT00960960Phase 1Report a problem
• Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based TherapyCompletedNCT00928330Phase 1Report a problem
• Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast CancerTerminatedNCT00864175Phase 1/2Report a problem
• Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple MyelomaCompletedNCT00847366Not applicableReport a problem
• Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast CancerTerminatedNCT00817362Phase 2Report a problem
• A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid TumorsTerminatedNCT00811993Phase 1Report a problem
• Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast CancerCompletedNCT00807859Phase 1Report a problem
• Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab TherapyCompletedNCT00803556Phase 1Report a problem
• A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast CancerCompletedNCT00788931Phase 1Report a problem
• Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast CancerCompletedNCT00788333Phase 1/2Report a problem
• A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive, not recruitingNCT00781612Phase 2Report a problem
• Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed HerceptinCompletedNCT00773344Phase 1/2Report a problem
• Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)CompletedNCT00736970Phase 2Report a problem
• Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By SurgeryTerminatedNCT00674414Phase 2Report a problem
• A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast CancerCompletedNCT00620594Phase 1Report a problem
• Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer PatientsCompletedNCT00485979Phase 2Report a problem
• Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast CancerCompletedNCT00426530Phase 1Report a problem
• CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD StudyCompletedNCT00412412Phase 1Report a problem
• Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and ImmunogenicityActive, not recruitingNCT00393783Phase 1Report a problem
• Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast CancerCompletedNCT00387907Phase 2Report a problem
• XRP9881 in Combination With Trastuzumab in Metastatic Breast CancerCompletedNCT00386685Phase 2Report a problem
• GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast CancerCompletedNCT00371488Phase 1Report a problem
• Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.CompletedNCT00367471Phase 1Report a problem
• Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast CancerCompletedNCT00343109Phase 2Report a problem
• A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast CancerCompletedNCT00337649Phase 1/2Report a problem
• Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous TrastuzumabCompletedNCT00301899Phase 2Report a problem
• Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the LungCompletedNCT00301730Phase 1Report a problem
• GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast CancerTerminatedNCT00251433Phase 1Report a problem
• PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast CancerTerminatedNCT00216047Phase 1/2Report a problem
• GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/NeuCompletedNCT00085020Phase 1Report a problem
• Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast CancerCompletedNCT00068757Phase 1Report a problem
• Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast CancerWithdrawnNCT00054470Phase 2Report a problem
• CPG 7909 Plus Herceptin® In Patients With Metastatic Breast CancerCompletedNCT00043394Phase 2Report a problem
• Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00042809Phase 1Report a problem
• Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast CancerTerminatedNCT00039455Phase 1Report a problem
• Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast CancerCompletedNCT00031278Phase 1/2Report a problem
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1Report a problem
• BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid TumorsCompletedNCT00022529Phase 1Report a problem
• Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1Report a problem
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1Report a problem

← Trastuzumab